Du är här


Peptonic Medical: Last day of trading in Peptonic paid subscribed shares

Stockholm, January 18th , 2016 - Peptonic Medical AB (publ) ("Peptonic
Medical" or the "Company") - a company developing pharmaceutical
products based on oxytocin - recently conducted a rights issue and a
private placement. A total of 9 732 452 new shares were issued
through the issues. Wednesday, January 20, 2016 is the last day of
trading in the paid subscribed shares and the stop day is on Friday,
January 22, 2016.

A total of 9 732 452 new shares have been registered with Bolagsverket
(the Swedish Companies Registration Office) and the total number of
shares in Peptonic Medical after the rights issue amounts to 19 174
412 shares and the share capital amounts to SEK 1 917 441.20.

For further information, please contact:

Johan Inborr, CEO

Phone: +46 708 853 893

E-mail: johan.inborr@peptonicmedical.se

About Peptonic Medical AB (publ)

Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical
company developing oxytocin based products e.g. for the treatment of
menopausal symptoms, such as vaginal atrophy. Oxytocin has a long
history of safe medical use and offers an alternative to estrogen and
estrogen-like acting compounds for menopausal and postmenopausal
women. Peptonic Medical AB (publ)'s mission is to develop safe and
effective drugs based on oxytocin.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.